Indivior Announces H1 and Q2 2022 Financial Results

Rhea-AI Summary

Indivior PLC (LON: INDV) reported its financial results for the period ending June 30, 2022. The company continues to focus on developing treatments for substance use disorders, with a pipeline that aims to address related chronic conditions. Earnings and investor presentation details are available on their website. The live webcast presentation hosted by CEO Mark Crossley is scheduled for July 28 at 1:00 PM BST. Indivior employs over 900 individuals globally and offers products in over 40 countries.

Positive

• Continued commitment to developing medicines for substance use disorders.
• Global portfolio of opioid use disorder treatments available in over 40 countries.

Negative

• None.

SLOUGH, U.K. and RICHMOND, Va., July 28, 2022  /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending June 30, 2022. The earnings release, investor presentation and webcast are available at www.indivior.com.

• The earnings release can be found at www.indivior.com/en/media/press-releases 
• The investor presentation can be found at www.indivior.com/investors by 7:00 a.m. EDT July 28, 2022

There will be a live webcast presentation at 13:00 BST (8:00 a.m. EDT) hosted by Mark Crossley, CEO. The details are below.

Webcast link: https://edge.media-server.com/mmc/p/n3frngii

Participants may access the presentation telephonically by registering here. 

(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-h1-and-q2-2022-financial-results-301594927.html

SOURCE Indivior

FAQ

What were Indivior's financial results for Q2 2022?

Indivior announced its financial results for the period ending June 30, 2022, focused on substance use disorder treatments.

When is the live webcast for Indivior's financial results?

The live webcast is scheduled for July 28, 2022, at 1:00 PM BST.

What is Indivior's focus area in pharmaceuticals?

Indivior focuses on developing treatments for substance use disorders and serious mental illnesses.

How many employees does Indivior have?

Indivior employs over 900 individuals globally.

In how many countries does Indivior have a presence?

Indivior's products are available in over 40 countries worldwide.